Hikma Pharmaceuticals Share Price (HIK)

1,938.00 -5.00 (-0.26%) delayed: 10:33AM GMT
Bid price 1,936.00 Open price 1,936.00
Ask price 1,938.00 Prev close 1,938.00
High price 1,948.00 Spread 0.10%
Low price 1,932.00 Volume 573,435

Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.

Hikma Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hikma Pharmaceuticals share price charts

Hikma Pharmaceuticals Share Price Information

Name Hikma Pharmaceuticals Epic HIK
Sector Pharmaceuticals & Biotechnology ISIN GB00B0LCW083
Activites Hima Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Index FTSE 100

Hikma Pharmaceuticals Key Numbers

Latest Share Price (p) 1,938.00 Net Gearing (%) 26.65
Market Capitalisation (£m) 4,662.32 Gross Gearing (%) 47.94
Shares in issue (m) 239.95 Debt Ratio 32.57
P/E Ratio 15.35 Debt-to-Equity Ratio 0.52
Total dividends per share (p) 32.00 Assets / Equity Ratio 1.92
Dividend Yield (%) 1.06 Price to book value 3.45
Dividend cover (x) 3.19 ROCE (%) 15.86
Earning per share (p) 126.60 EPS Growth (%) -9.83
52 week high / low 2,703.00 / 1,575.00 DPS Growth (%) 45.45

Hikma Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
20/12/2016 BUY Ali Al-Husry NED 140,730
20/12/2016 BUY Mazen Darwazah ED 140,730
20/12/2016 BUY Said Darwazah CH 140,730
13/12/2016 BUY Ali Al-Husry NED 50,000
13/12/2016 BUY Mazen Darwazah ED 50,000

More Hikma Pharmaceuticals Director Deals >>

Hikma Pharmaceuticals Company News

09:20 18/01/2017

Hikma unit gets FDA approval for narcolepsy drug

Hikma Pharmaceuticals' wholly-owned US subsidiary, Roxane Laboratories, has received an approval for its generic equivalent to Xyrem from the US Food and Drug Administration. Roxane's Sodium Oxybate oral solution 500 mg/mL is indicated for the treatment of cataplexy (sudden loss of muscle...

09:11 18/01/2017

Hikma receives approval for Sodium Oxybate

RNS Number : 4587U Hikma Pharmaceuticals Plc 18 January 2017   Hikma receives approval for Sodium Oxybate Oral Solution   London, 18 January 2017   - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P,...

12:00 04/01/2017

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2100p (from 2450p). Story provided by StockMarketWire.com

More Hikma Pharmaceuticals Company News >>

Register now for FREE Hikma Pharmaceuticals company news

Hikma Pharmaceuticals Share Price Discussions

more than 1 year ago

Hikma Pharmaceuticals (HIK)

Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...

Register now for FREE Hikma Pharmaceuticals share price discussions